Navigation Links
Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints

c dermatitis is a chronic childhood skin condition that may affect patients for many years. Dermatology agents currently used to treat atopic dermatitis and other inflammatory skin disorders have important limitations and two commonly used immunosuppressants have been the subject of a controversial FDA imposed "black box" warning of a potential link between long term use and certain cancer risks. The use of EpiCeram(TM) does not raise any of the major safety concerns associated with the use of topical steroids and immunosuppressants.

Steve Porter, Ceragenix's Chairman and CEO stated, "We are very pleased with these results. We have just demonstrated that EpiCeram(TM) is comparable to a mid strength steroid in treating the symptoms of atopic dermatitis after a 28 day treatment regimen. We believe that EpiCeram has the potential to become the foundation of a new and improved paradigm in the treatment of this common childhood skin disorder which affects over 15 million Americans."

Study Design

The study was an investigator-blinded, randomized controlled study conducted at five centers which evaluated a total of 113 patients in two groups of children (ages 6 months to 18 years) with moderate-to-severe atopic dermatitis treated with either Cutivate(R) Cream, a mid-potency topical steroid, or EpiCeram(TM). The study was primarily conducted during the winter months of December ('06), January ('07) and February ('07).

Primary and Secondary Outcome Measures.

According to the protocol, the primary outcome measure was the change in mean SCORAD score measured at Day 28 as compared to the baseline. The protocol's secondary efficacy parameters were: -0-

       a) Percentage of subjects reaching clear or almost clear on

          Investigator's Global Assessment (IGA) at Day 28;

       b) Change in patient reported assessments of pruritus (itch);

          and

       c) Change in patient reported assessment of disturbance of

      
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
2. Ceragenix Announces New Publication of Scientific Research on Ceragenin Technology
3. Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:8/29/2014)... 29, 2014 According to ... & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), ... QPCR, Gene Synthesis, NGS, DNA, RNAi) - Global ... Oligonucleotide Synthesis Market is expected to reach $1,712.1 ... growing at a CAGR of 9.8% from 2014 ...
(Date:8/29/2014)... 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... intends to release its financial results for the fiscal ... after market trading ends on Tuesday, September 9, 2014. ... for 4:30 p.m. U.S. EDT on Tuesday, September 9, ... review the Company,s financial results, commercial partnerships, and future ...
(Date:8/29/2014)... 2014 Research and Markets has ... Drugs Market 2014-2018" report to their offering. ... condition that results in demyelination, axonal transection, and neurodegeneration. ... response by the immune system, which targets neurons within ... debilitating disease in which the damage of the myelin ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... , MOUNTAIN VIEW, Calif. , Jan. ... system solutions to acute healthcare facilities, today announced results for its fourth ... results: Revenue for the fourth quarter of 2009 was $54.7 ... quarter of 2009, and down $7.4 million or 11.9% from ...
... , ORLANDO, Fla. , Jan. 28 ... advisor Hal Broxmeyer , Ph.D., on becoming the 2010 President ... President of such an important organization as ASH is a tremendous ... work that Dr. Broxmeyer has performed, and we are deeply honored ...
Cached Medicine Technology:Omnicell Announces Fourth Quarter and Full-Year 2009 Results 2Omnicell Announces Fourth Quarter and Full-Year 2009 Results 3Omnicell Announces Fourth Quarter and Full-Year 2009 Results 4Omnicell Announces Fourth Quarter and Full-Year 2009 Results 5Omnicell Announces Fourth Quarter and Full-Year 2009 Results 6Omnicell Announces Fourth Quarter and Full-Year 2009 Results 7Omnicell Announces Fourth Quarter and Full-Year 2009 Results 8Omnicell Announces Fourth Quarter and Full-Year 2009 Results 9Omnicell Announces Fourth Quarter and Full-Year 2009 Results 10Omnicell Announces Fourth Quarter and Full-Year 2009 Results 11Omnicell Announces Fourth Quarter and Full-Year 2009 Results 12Omnicell Announces Fourth Quarter and Full-Year 2009 Results 13Omnicell Announces Fourth Quarter and Full-Year 2009 Results 14CORD:USE Cord Blood Bank Congratulates Team Member Hal Broxmeyer, Ph.D., on his Election as President of the American Society of Hematology 2CORD:USE Cord Blood Bank Congratulates Team Member Hal Broxmeyer, Ph.D., on his Election as President of the American Society of Hematology 3
(Date:8/30/2014)... plant-based medication commonly used to treat gout, before ... reducing potential complications from this type of surgery, ... adverse effects, according to a study published by ... early online to coincide with its presentation at ... complications after cardiac surgery include postpericardiotomy syndrome (the ...
(Date:8/30/2014)... 30, 2014 "My niece developed a ... at any moment, her fever might get worse," said ... me well aware of how she was doing, I ... ALARM to continuously monitor a child's temperature. The unit ... This ensures that prompt medical care can be given, ...
(Date:8/30/2014)... 30, 2014 Bringing forth the great ... announces the Labor Day discount on all SEO ... get the complete services related to internet marketing. Their ... Writers, and others do have a deep understanding for ... in their work and since the inception, they have ...
(Date:8/30/2014)... "I had a handicapped friend who could not walk along ... Wetumpka, Ala. "In order to help her be able to ... up with a way for her to use her crutches ... patent-pending Deezers to allow crutches to be used on uneven ... or canes at the beach. The device reduces the risk ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
Breaking Medicine News(10 mins):Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... that are not often discussed like cross-dressing, homosexuality and ... international film festival on gender and sexuality, which attracted ... ,Brought together by the Public Service Broadcasting ... and UNESCO, the four-day festival at the India Habitat ...
... Love revealed that she chants as she decides what to ... ,Chanting is used by many Buddhists celebrities including Tina ... ,Love reportedly wrote on her website: "I chanted two ... go." ,She is deciding between having a private ...
... Spanish Wine Fair (Fenavin) here, India has said it ... in production if a strong element of "price sensitivity" ... necessarily mean selling the cheapest wine," Subhash Arora, president ... three-day fair Wednesday. ,India already has a ...
... at least six years away for talented actress Kangana Ranaut but ... she wants in Mr.Right! ,"I'm going to get ... years to find Mr. Right," Kangana told IANS. ... has to be a white-collar professional like a doctor or a ...
... to have found a treatment, which could block the action ... cancer. ,The enzyme PTP1B appears to fuel tumor ... in treating the disease. About 40 percent of human breast ... this enzyme. ,Michel Tremblay and colleagues at McGill ...
... school bullying has decided to give more power to school ... ,The Prime Minister will announce this move at a meet ... ,Yet, critics of the Prime Minister like the ... this is nothing new. ,New South Wales Education ...
Cached Medicine News:Health News:Film Festival on Gender Sexuality Draws Crowds 2Health News:India is Uncorking Its Wine Market: Expert 2Health News:Gentle, Real, Well-mannered - Kangana's Mr. Right 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: